$3.81 Earnings Per Share Expected for United Therapeutics Co. (NASDAQ:UTHR) This Quarter

Equities research analysts expect United Therapeutics Co. (NASDAQ:UTHRGet Rating) to report earnings of $3.81 per share for the current quarter, Zacks reports. Five analysts have made estimates for United Therapeutics’ earnings, with the lowest EPS estimate coming in at $3.42 and the highest estimate coming in at $4.35. United Therapeutics posted earnings per share of $3.65 during the same quarter last year, which suggests a positive year-over-year growth rate of 4.4%. The company is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that United Therapeutics will report full year earnings of $16.77 per share for the current year, with EPS estimates ranging from $15.06 to $17.70. For the next year, analysts forecast that the firm will post earnings of $18.15 per share, with EPS estimates ranging from $16.08 to $19.12. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHRGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported $5.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $2.07. United Therapeutics had a net margin of 38.87% and a return on equity of 17.62%. The company had revenue of $461.90 million for the quarter, compared to the consensus estimate of $420.02 million. During the same period last year, the firm posted $0.61 EPS. United Therapeutics’s revenue for the quarter was up 21.8% on a year-over-year basis.

Several brokerages have issued reports on UTHR. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $230.00 to $223.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 19th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $175.00 price objective on the stock. in a research report on Tuesday, March 1st. BTIG Research assumed coverage on shares of United Therapeutics in a report on Friday, February 11th. They issued a “neutral” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of United Therapeutics in a report on Friday, February 25th. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $275.00 to $300.00 in a report on Thursday, May 5th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $223.67.

United Therapeutics stock traded up $2.02 during midday trading on Friday, hitting $188.33. 466,013 shares of the company’s stock were exchanged, compared to its average volume of 426,012. United Therapeutics has a 12-month low of $158.38 and a 12-month high of $218.38. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.54 and a current ratio of 8.84. The stock has a market cap of $8.53 billion, a price-to-earnings ratio of 13.03, a price-to-earnings-growth ratio of 4.24 and a beta of 0.64. The firm’s 50 day simple moving average is $183.26 and its 200 day simple moving average is $192.12.

In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $182.42, for a total value of $1,094,520.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 36,000 shares of company stock valued at $6,631,920 in the last quarter. Company insiders own 12.10% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in United Therapeutics by 0.9% during the first quarter. BlackRock Inc. now owns 4,277,089 shares of the biotechnology company’s stock worth $767,350,000 after acquiring an additional 37,914 shares during the last quarter. Wellington Management Group LLP raised its position in shares of United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after buying an additional 710,668 shares during the last quarter. State Street Corp raised its position in shares of United Therapeutics by 7.2% in the first quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock valued at $291,809,000 after buying an additional 109,226 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of United Therapeutics by 17.1% in the third quarter. Bank of New York Mellon Corp now owns 844,958 shares of the biotechnology company’s stock valued at $155,962,000 after buying an additional 123,295 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of United Therapeutics by 9.0% in the fourth quarter. Geode Capital Management LLC now owns 760,948 shares of the biotechnology company’s stock valued at $164,425,000 after buying an additional 62,882 shares during the last quarter. Institutional investors own 94.68% of the company’s stock.

About United Therapeutics (Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.